Christer Nordstedt
Presidente presso WNTRESEARCH AB
Profilo
Christer Nordstedt is currently the Chief Executive Officer at Oblique Therapeutics AB, Chairman at Wntresearch AB, and Director at IRLAB Therapeutics AB.
He previously served as the Chief Executive Officer at Vivesto AB in 2022, Senior Vice President-Research & Development at Orion Oyj from 2017 to 2020, and Global Research Manager at Teva GmbH.
Nordstedt holds a doctorate degree from Karolinska Institutet, conferred in 1991.
Posizioni attive di Christer Nordstedt
| Società | Posizione | Inizio |
|---|---|---|
| WNTRESEARCH AB | Presidente | 01/01/2022 |
| IRLAB THERAPEUTICS AB | Direttore/Membro del Consiglio | 01/01/2023 |
| Snevringe AB | Presidente | - |
Oblique Therapeutics AB
 Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Amministratore Delegato | 01/12/2022 |
CINDA PHARMA AB
 CINDA PHARMA AB Miscellaneous Commercial ServicesCommercial Services CINDA PHARMA AB is a Swedish company that engages in the research and development of pharmaceutical products. The private company is located in Sweden. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Christer Nordstedt
| Società | Posizione | Fine |
|---|---|---|
| VIVESTO AB | Amministratore Delegato | 30/11/2022 |
| ORION OYJ | Direttore Tecnico/Scientifico/R&S | 05/03/2020 |
| Fermion Ltd. | Direttore/Membro del Consiglio | 01/01/2020 |
| Orion Diagnostica AB | Direttore/Membro del Consiglio | 01/01/2019 |
| ░░░ ░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Christer Nordstedt
| Karolinska Institutet | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| ORION OYJ | Health Technology |
| VIVESTO AB | Health Technology |
| WNTRESEARCH AB | Health Technology |
| IRLAB THERAPEUTICS AB | Health Technology |
| Aziende private | 9 |
|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Hoffman-LaRoche F & Co. AG
 Hoffman-LaRoche F & Co. AG Miscellaneous Commercial ServicesCommercial Services Hoffman-LaRoche F & Co. AG is a Swiss company. | Commercial Services |
Teva GmbH
 Teva GmbH Medical DistributorsDistribution Services Part of Teva Pharmaceutical Industries Ltd., Teva GmbH is a German company that aims to provide high-quality medications to improve the quality of life for patients. The company is based in Ulm, Germany. The CEOs are Andreas Burkhardt, Thomas Andreas Schlenker. The company was founded in 2011 by Chaim Salomon, Günther Friedländer, Moshe Levinson, Yitschak Elstein. | Distribution Services |
| Eli Lilly Sweden AB | |
| Orion Diagnostica AB | |
| Fermion Ltd. | |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |
| Snevringe AB | |
CINDA PHARMA AB
CINDA PHARMA AB Miscellaneous Commercial ServicesCommercial Services CINDA PHARMA AB is a Swedish company that engages in the research and development of pharmaceutical products. The private company is located in Sweden. | Commercial Services |
- Borsa valori
- Insiders
- Christer Nordstedt
